LINE-1 in the brain

LINE-1 is a stretch of virus-like DNA that can copy itself into new places in the genome. These insertions build up in the brain over a person's lifetime, and they may occur much faster in certain brain disorders. Fragments of DNA from failed insertions are produced in this process, and the cell recognizes them as foreign DNA, which triggers an immune reaction

A disorder where LINE-1 is particularly prominent is Ataxia-Telangiectasia (A-T), where patients experience progressive neurodegeneration and aging-like features. It is caused by mutations in the ATM gene, which leave cells less able to detect and repair DNA damage. As a result, LINE-1 may insert itself at broken sites in DNA. This process depends only on LINE-1's ability to copy RNA back into DNA (reverse transcriptase), rather than on its DNA-cutting activity (endonuclease). In mouse studies, increasing LINE-1 activity in brain regions affected in A-T was enough to cause ataxia-like symptoms, and treatment with nucleoside reverse transcriptase inhibitors (NRTIs) slowed disease progression

In the brain, the process occurs continuously and depends only on LINE-1's ability to copy RNA back into DNA. In Rett syndrome, however, this process depends on DNA cutting as well (similar to in cancer). Rett syndrome is a progressive neurodevelopmental disorder caused by mutations in MECP2. Changes in DNA methylation, which helps regulate gene activity, increase LINE-1 expression and lead to more insertions. Although these insertions are less frequent than in A-T, they are still significantly higher than normal brain levels, and NRTIs also slow disease progression in mouse models of Rett

Together, these findings suggest that LINE-1 is not just a byproduct of disease, but may actively contribute to brain damage. Because LINE-1 insertions also accumulate over time in healthy brains at higher levels than in other tissues, LINE-1 matters not only for people with rare disorders, but for brain aging more broadly. The challenge, however, for disorders such as A-T and Rett, is that damage occurs very early in development. Therefore, inhibiting LINE-1 can only slow disease progression. But there are situations where inhibiting LINE-1 may meaningfully change the trajectory of a disease